Balaji Amines Ltd
Balaji Amines Ltd Q3 FY25 Results & Presentation Highlights: Revenue ₹321 Cr, PAT ₹31 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaji Amines Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Q3FY25 Consolidated EBITDA: ₹54 crore, down 35% YoY from ₹83 crore in Q3FY24 (Page 6) - Q3FY25 Consolidated EBITDA margin: 17%, down from 21% in Q3FY24 (Pages 6 and 7) - Q3FY25 Consolidated Profit
From Balaji Amines Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7).
- Total volumes in Q3FY25 stood at 24,097 MT vs. 26,348 MT in Q2FY25; no direct YoY volume comparison provided (Page 7).
- Segment volumes for Q3FY25: Amines 7,515 MT, Amines Derivatives 8,809 MT, Specialty Chemicals 7,773 MT (Page 7).
- Standalone revenue for Q3FY25 was ₹305 crore, down 3% YoY from ₹315 crore (Page 6).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Greenfield Phase 2 & 3 Capex: Ongoing, to be completed by FY 2026, includes n-Butylamine plant (15,000 TPA), Dimethyl Ether (DME) plant (100,000 TPA) commissioning expected by June 2025, and increased capacity utilization of Phase 1 Ethylamines plant.
- n-Butylamine plant: Market demand ~8,000 tons, executed on schedule.
- Methylamines capacity expansion: From 48,000 TPA to 88,000 TPA, commissioned Nov 2024.
- NBPT plant (N-(N-Butyl) Thiophosphoric Triamide): 2,500 TPA, planned for next financial year.
- ACN plant at Unit-III MIDC Chincholi: 60 MT/Day capacity, under detailed engineering, expected commissioning FY 2025-26.
- Subsidiary Balaji Speciality Chemicals: Rs. 750 crore phased expansion with Mega Project status covering multiple chemicals (e.g., Hydrogen Cyanide, Sodium Cyanide, EDTA).
- Solar Power Plant: 20 MW capacity near MIDC Chincholi; Phase 1 (8 MW DC) expected commissioning FY 2024-25.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Himadri Speciality Chemical Ltd (Q3 FY25)
1,131.81 Crs, up 7.53% YoY (from Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 investor presentation — and how it ranks
- Gujarat Alkalies & Chemicals Ltd (Q3 FY25)
3,702.77 Crores (up from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 investor presentation — and how it ranks agains
- Vidhi Specialty Food Ingredients Ltd (Q3 FY25)
Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 investor presentation —
- Chemcon Speciality Chemicals Ltd (Q3 FY25)
54.4 Cr, up 3% YoY from Rs. Key investor presentation takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY25 investor presentation — and how it ranks against
Frequently Asked Questions
What were Balaji Amines Ltd Q3 FY25 results?
Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Q3FY25 Consolidated EBITDA: ₹54 crore, down 35% YoY from ₹83 crore in Q3FY24 (Page 6) - Q3FY25 Consolidated EBITDA margin: 17%, down from 21% in Q3FY24 (Pages 6 and 7) - Q3FY25 Consolidated Profit
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Unit 4 Greenfield Phase 2 & 3 Capex: Ongoing, to be completed by FY 2026, includes n-Butylamine plant (15,000 TPA), Dimethyl Ether (DME) plant (100,000 TPA) commissioning expected by June 2025, and increased capacity utilization of Phase 1 Ethylamines plant.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.